Definium Therapeutics (DFTX) Interest Coverage Ratio (2023 - 2026)
Definium Therapeutics (DFTX) posted quarterly Interest Coverage Ratio of 0.0 for Q1 2026, up 100.0% year-over-year from 0.0 in Q1 2025, and up 100.0% quarter-over-quarter from 42.33 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Interest Coverage Ratio (2023 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Interest Coverage Ratio for 6 consecutive years, with 0.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 100.0% year-over-year to 0.0; the TTM figure through Mar 2026 stood at 0.0 (up 99.99% YoY), while the FY2025 annual figure was 0.01, up 78.52% from the prior year.
- Interest Coverage Ratio improved to 0.0 in Q1 2026 per DFTX's latest filing, from 42.33 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.0 in Q1 2026 and bottomed at 379.01 in Q2 2023.
- Historically, Interest Coverage Ratio has averaged 68.28 across 5 years, with a median of 35.13 in 2025.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio sank 13973.04% — and 2026, when it soared 100.0%.
- Definium Therapeutics' Interest Coverage Ratio stood at 0.38 in 2022, then plunged by 6934.18% to 27.08 in 2023, then slumped by 82.74% to 49.48 in 2024, then advanced by 14.46% to 42.33 in 2025, then soared by 100.0% to 0.0 in 2026.
- Business Quant data shows DFTX's Interest Coverage Ratio at 0.0 in Q1 2026, 42.33 in Q4 2025, and 35.13 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | -60.89 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60.89 |
| Mar 31, 2026 | -47.57 |
| Dec 31, 2025 | -37.00 |
| Sep 30, 2025 | -35.13 |
| Jun 30, 2025 | -17.49 |
| Mar 31, 2025 | -53.42 |
| Dec 31, 2024 | -49.48 |
| Sep 30, 2024 | -34.10 |
| Jun 30, 2024 | -52.48 |
| Mar 31, 2024 | -51.16 |
| Dec 31, 2023 | -50.58 |
| Sep 30, 2023 | -65.90 |
| Jun 30, 2023 | -379.01 |
| Mar 31, 2023 | -274.50 |